Clinical trial NCT06996704: A Clinical Study of AK0610
Official title: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation, and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of AK0610 in Healthy Chinese Adults.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Healthy Volunteer Study
Keywords: Phase 1 study of AK0610
Lead sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-05-30
Enrollment: 136
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The study consists of two parts: dose escalation and expansion. It includes five cohorts in the dose-escalation phase and two expansion cohorts based on pharmacokinetic data.

Detailed description: This study is a Phase I clinical trial that is randomized, double-blind, placebo-controlled, and involves single-dose administration, dose-escalation, and an expansion phase. It evaluates the safety, tolerability, and pharmacokinetic profile of AK0610 in healthy Chinese adults.

The study consists of two parts. The dose-escalation phase includes five cohorts (100 mg i.m.; 300 mg i.m.; 300 mg i.v.; 1000 mg i.v.; 3000 mg i.v.), each consisting of 8 individuals (AK0610: Placebo = 3:1), who are administered doses in sequential increments.

Based on pharmacokinetic data, the dose-escalation phase will be expanded to include two additional dose cohorts (300 mg i.m.; 600 mg i.m.) of 48 individuals each (AK0610: Placebo = 3:1).

Each participant will undergo a Screening Period from Day -29 to Day -1. They will receive one dose on Day 1, an Inpatient Observation Period from Day -1 to Day 8, and a Blinded Follow-Up Period from Day 9 to Day 181. Subjects in the AK0610 group will also enter an open-label period from Day 182 to Day 361.

Eligibility criteria: Inclusion Criteria:

1. Participants aged 18 - 50 (both males and females)
2. Males weighing ≥50 kg, females weighing ≥45 kg, and BMI 18-28 kg/m2.
3. Assessed by the investigator to be in good health with no clinically significant abnormalities.
4. Use of highly effective contraception within 1 year of administration.
5. Voluntary participation in clinical research and signing of written informed consent.

Exclusion Criteria:

1. Clinically significant cardiovascular, respiratory, hepatic, renal, hematologic (e.g., bleeding disorders), gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychiatric system disorders, or any other condition that, in the opinion of the Investigator, may jeopardize subject safety or validity of the study results, or that may result in the inability of the subject to complete the study in accordance with the protocol.
2. Active malignancy and/or a history of malignancy (except for basal cell carcinoma of the skin that has been treated without evidence of recurrence)
3. History of congenital or acquired immunodeficiency.
4. Acute illness, such as fever, infectious disease, diarrhea, etc., occurring within 1 week prior to the subject's first dose.
5. Major surgery within 3 months prior to screening or major surgery planned within 1 year of study drug administration.
6. Hypersensitivity to the active ingredient of AK0610 or any excipients.
7. Previous history of allergy to biologics or history of severe allergic reaction (e.g. hypotension, dyspnea, severe angioedema) to any drug.
8. Human immunodeficiency virus (HIV) antibody positive; hepatitis C virus (HCV) antibody positive or hepatitis B surface antigen (HBsAg) positive; syphilis spirochete antibody positive.
9. Systolic blood pressure ≥140 mmHg or \<90 mmHg or diastolic blood pressure ≥90 mmHg or \<60 mmHg, and pulse \<55 or \>100 beats/min.
10. ECG suggestive of prolonged QTcF (≥450 ms in both women and men). \[QTcF= QT/(RR\^0.33)\]
11. Use of any prescription, over-the-counter, herbal, proprietary, or health care product (other than birth control pills) within 14 days prior to study drug administration.
12. Have received treatment with immune globulin or other blood products within 6 months prior to study drug administration
13. Have received treatment with monoclonal antibodies or other biological products within 6 months prior to administration of study drug.
14. Have received a live attenuated vaccination within 1 month prior to study drug administration, has received another vaccination within 14 days, or is scheduled to receive a vaccination within 1 year of study drug administration.
15. Received any other investigational drug therapy within 3 months (or 5 half-lives, whichever is longer) prior to study drug administration, or plans to participate in another study within 1 year of study drug administration.
16. Participating or have participated in another interventional clinical study of a monoclonal antibody or vaccine against RSV.

Primary outcomes:
measure: Incidence and severity of treatment-emergent adverse events (TEAEs)
timeFrame: Up to 361 days
Secondary outcomes:
measure: Maximum Observed Serum Concentration (Cmax) of AK0610
timeFrame: Up to 361 days
measure: Time to Reach Maximum Observed Serum Concentration (Tmax) of AK0610
timeFrame: Up to 361 days
measure: Area Under the serum concentration-time curve from time 0 to the last measurable concentration (AUC₀-t) of AK0610
timeFrame: Up to 361 days
measure: Area Under the serum concentration-time curve from time 0 to extrapolated to infinite time (AUC (0-infinity) ) of AK0610
timeFrame: Up to 361 days
measure: Terminal Elimination Half Life (t1/2) of AK0610
timeFrame: Up to 361 days
measure: Extravascular Clearance (CL/F (intramuscular administration)) of AK0610
timeFrame: Up to 361 days
measure: Apparent Volume of Distribution (Vd/F (intramuscular administration)) of AK0610
timeFrame: Up to 361 days
measure: CL(IV administration) of AK0610
timeFrame: Up to 361 days
measure: Vd (IV administration) of AK0610
timeFrame: Up to 361 days
measure: To assess the changes in serum RSV-neutralizing activity after a single intramuscular or intravenous injection of AK0610 in healthy Chinese subjects
timeFrame: Up to 361 days
measure: To assess the immunogenicity of a single intramuscular or intravenous injection of AK0610 in healthy Chinese subjects.
timeFrame: Up to 361 days
Other outcomes:
Locations:
city: Jinan
country: China
facility: The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital ）
state: Shandong
Study officials:
References: